Preparation and evaluation of ¹⁸⁸Re-labeled octreotide analog in C6 glioma tumor

In the present study, preparation of [¹⁸⁸Re]Re-Tricine-HYNIC-Tyr³-octreotide, stability in human serum, internalization, cell viability analysis, and in vivo tissue biodistribution in rats bearing C6 glioma tumor were investigated. Radiolabeled peptide exhibited a molar activity of 8.60 ± 0.76 GBq/µmol, with over 90% (n = 3) of radiochemical yield. The findings indicated significant internalization of radiolabeled peptide into glioma cells and the ability to reduce cancerous cell viability in MTT analysis. High tumor-to-muscle ratios were observed at various time points following injection. The results suggest that the radiolabeled peptide could be considered for treating tumors expressing somatostatin receptors.